<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998345</url>
  </required_header>
  <id_info>
    <org_study_id>SSGJ-609-UND-I-01</org_study_id>
    <nct_id>NCT03998345</nct_id>
  </id_info>
  <brief_title>Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China</brief_title>
  <official_title>A First-in-Human, Open-label, Phase 1 Dose-Escalation Study of 609A in Subjects With Locally Advanced/Metastatic Solid Tumors in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in the Patients with&#xD;
      Locally advanced/Metastatic Solid Tumors in China.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human (FIH), open-label, phase 1 dose-escalation study of 609A in China, a&#xD;
      recombinant monoclonal anti-PD-1 antibody product, in subjects with Locally&#xD;
      advanced/Metastatic Solid Tumors, who must have failed standard treatment (disease&#xD;
      progression or intolerance) or lack of standard treatment. If there is a driver gene variant,&#xD;
      the subjects must have failed the standard treatment for the driver gene, and there is no&#xD;
      other standard treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-Emergent Adverse Events</measure>
    <time_frame>for 90 days</time_frame>
    <description>To access adverse events (AEs) per the NCI CTCAE 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The MTD</measure>
    <time_frame>for 90 days</time_frame>
    <description>Maximum Tolerated Dose， if any, and RP2D (s) for 609A will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>for 90 days</time_frame>
    <description>Area Under the Curve of 609A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>for 90 days</time_frame>
    <description>Maximum Plasma Concentration of 609A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>for 90 days</time_frame>
    <description>Half life of 609A in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>for 90 days</time_frame>
    <description>Plasma clearance of 609A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>for 1 year</time_frame>
    <description>the rate of completely response [CR] and partial response [PR] patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>for 1 year</time_frame>
    <description>disease control rates of the patients with 609A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>for 1 year</time_frame>
    <description>Duration of response of the patients with 609A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>for 1 year</time_frame>
    <description>Progression-free survival of the patients with 609A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>for 1 year</time_frame>
    <description>overall survival of the patients with 609A</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA</measure>
    <time_frame>for 1 year</time_frame>
    <description>to detect the presence of anti-609A antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1</measure>
    <time_frame>for 1 year</time_frame>
    <description>to evaluate the expression of pd-l1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>609A group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation will be conducted using a traditional 3+3 design. Dose Escalation Level cohort 1. Dose 1 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 2. Dose 3 mg/kg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 3. Dose 200mg, Q3W, IV. Subjects 3-6； Dose Escalation Level cohort 4. Dose 10 mg/kg, Q3W, IV. Subjects 3-6. If 10mg/kg cannot be tolerated, add a dose level of 400mg to assess the tolerance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>609A</intervention_name>
    <description>609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1</description>
    <arm_group_label>609A group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all the following inclusion criteria to be eligible for participation in&#xD;
        this study:&#xD;
&#xD;
          -  Able to understand and willing to sign the Informed Consent Form(ICF).&#xD;
&#xD;
          -  No limit gender .&#xD;
&#xD;
          -  Age range: from 18 years to 70 years.&#xD;
&#xD;
          -  Subjects with histologically or cytologically confirmed locally advanced-stage or&#xD;
             metastatic tumor must have failed standard treatment (disease progression or&#xD;
             intolerance) or lack of standard treatment. If there is a driver gene variant, the&#xD;
             subjects must have failed the standard treatment for the driver gene, and there is no&#xD;
             other standard treatment.&#xD;
&#xD;
          -  Patients who had been previously treated for brain metastases, must have asymptomatic&#xD;
             or radiographic/clinical stability and no need for steroid therapy of brain metastases&#xD;
             to be enrolled in this study within 4 weeks prior to enrollment .&#xD;
&#xD;
          -  According to RECIST1.1, Patients must have at least one measurable lesion (target or&#xD;
             non-target).&#xD;
&#xD;
          -  ECOG scores 0,1 or 2.&#xD;
&#xD;
          -  Life expectancy ≥3 months&#xD;
&#xD;
          -  Must have adequate organ function, prior to start of 609A, including the following:&#xD;
&#xD;
               1. Bone marrow reserve: absolute neutrophil count (ANC) ≥ 1.0 ×109/L; platelet&#xD;
                  count≥ 100 × 109/L; hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L;&#xD;
&#xD;
               2. Hepatic: total bilirubin ≤ 1.5 times the upper limit of normal (ULN), aspartate&#xD;
                  transaminase (AST) and/or alanine aminotransferase (ALT) ≤ 3 × ULN (≤5 × ULN if&#xD;
                  with liverinvolvement)&#xD;
&#xD;
               3. Renal: serum creatinine ≤1.5 times the ULN or estimated creatinineclearance&#xD;
                  ≥50mL/min (Cockroft and Gault formula).&#xD;
&#xD;
               4. Coagulation tests INR≤ 2 (Exception: INR 2 to ≤ 3 is acceptable for subjects on&#xD;
                  Warfarin anticoagulation), activated partial thromboplastin time (aPTT) ≤ 1.5 ×&#xD;
                  ULN&#xD;
&#xD;
          -  Female patient with fertility or male patient whose partner has fertility should use&#xD;
             one or more contraceptive methods for contraception from the screening period to five&#xD;
             half-lives after the last treatment. These measures include, but are not limited to,&#xD;
             oral or implantable injections of hormonal contraceptives; intrauterine birth control&#xD;
             ring or placement of intrauterine system (IUS) hormone-releasing intrauterine device;&#xD;
             or use of barrier methods such as condoms or septum and spermicide products. Women of&#xD;
             childbearing potential must have a negative pregnancy test ≤ 72 hours prior to the&#xD;
             first dose of study drug. Postmenopausal women must have been amenorrhoeic for at&#xD;
             least 12 months to be considered of non-childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria will not be enrolled:&#xD;
&#xD;
          -  History of life-threatening hypersensitivity or known to be allergic to protein drugs&#xD;
             or recombinant proteins or excipients in 609A drug formulation.&#xD;
&#xD;
          -  Subjects who had experienced severe allergic reactions after administration of other&#xD;
             monoclonal antibodies&#xD;
&#xD;
          -  Pregnant or nursing females&#xD;
&#xD;
          -  Regarding previous anti-tumor therapy:&#xD;
&#xD;
               1. Subjects who have received any anticancer drugs approved or investigational,&#xD;
                  including chemotherapy,hormonal therapy (Exceptions: hormone-replacement therapy,&#xD;
                  testosterone or oral contraceptives), biologic therapy, have stopped treatment&#xD;
                  for less than 3 weeks or 5 half-lives, whichever is longer, before first dose of&#xD;
                  609A.&#xD;
&#xD;
               2. Subjects who have stopped systemic radiation therapy less than 3 weeks before&#xD;
                  first dose of 609A, or local radiotherapy or radiation therapy for bone&#xD;
                  metastases less than 2 weeks before first dose of 609A. Therapeutic&#xD;
                  radiopharmaceuticals were taken within 8 weeks before first dose of 609A.&#xD;
&#xD;
               3. Subjects who have received prior immunotherapies targeting T cell stimulation&#xD;
                  such as (e.g. anti-PD-1, anti- PD-L1 or anti-CTLA-4) ,have stopped treatment less&#xD;
                  than 3 months before first dose of 609A.&#xD;
&#xD;
               4. The ADA antibody of anti-PD-1 drug in plasma was positive during screening.&#xD;
&#xD;
               5. Subjects who have received immunogonists (such as interleukin-2 gamma interferon,&#xD;
                  oncolytic virus, mistletoe extract, etc.) or drugs known to interfere with major&#xD;
                  organ function (e.g., hypericin) , have stopped treatment less than 4 weeks or 5&#xD;
                  half-lives, whichever is longer, before first dose of 609A.&#xD;
&#xD;
          -  Subjects with severe chronic or active infections requiring systemic antimicrobial,&#xD;
             antifungal, or antiviral treatment, including tuberculosis.&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Active hepatitis B or C. HBV carriers without active disease (HBV DNA titer&lt; 1000&#xD;
             cps/mL or 200 IU/mL) or cured Hepatitis C (negative HCV RNA test) may been rolled&#xD;
&#xD;
          -  Subjects with history of interstitial lung disease or noncommunicable pneumonia, or&#xD;
             uncontrolled pulmonary fibrosis or acute pulmonary disease . Local interstitial&#xD;
             pneumonia due to radiotherapy was excluded.&#xD;
&#xD;
          -  Acute or chronic uncontrolled renal disease( Exception: Renal carcinoma, metastatic&#xD;
             renal cancer), pancreatitis or liver disease (per investigator assessment).&#xD;
&#xD;
          -  Any remaining AEs &gt; grade 1 from prior anti-tumor treatment as per CTCAE v5. 0, with&#xD;
             exception of the residual hair loss.&#xD;
&#xD;
          -  Any SAE occurred during previous pd-1 / pd-l1 treatment, including but not limited to&#xD;
             interstitial pneumonia and myocarditis.&#xD;
&#xD;
          -  Subjects who experienced immunotherapy-related adverse events (irAE) grade ≥ 3, or who&#xD;
             had to discontinue prior anti-PD-1, anti-PD-L1, or CTL4 treatment due to irAEs of any&#xD;
             grade&#xD;
&#xD;
          -  Subjects with acute myocardial infarction, unstable angina pectoris, stroke, or&#xD;
             transient ischemic attack occurred within 6 months prior to admission. Subjects with&#xD;
             congestive heart failure rated as grade 2 or above (including grade 2) by the New York&#xD;
             college of cardiology (NYHA) ,LVEF&lt;50%.And subjects with the following heart diseases:&#xD;
&#xD;
               1. ECG QTcF&gt; 480 msec during screening.&#xD;
&#xD;
               2. Right bundle branch block and left anterior half branch block or complete left&#xD;
                  bundle branch block.&#xD;
&#xD;
               3. Subjects with congenital long QT syndrome or a family history of unexpected&#xD;
                  sudden cardiac death.&#xD;
&#xD;
               4. Subjects with ventricular tachyarrhythmia or history of tachyarrhythmia.&#xD;
&#xD;
               5. Bradycardia with obvious clinical significance (&lt; 50 times/min).&#xD;
&#xD;
               6. Subjects using pacemakers.&#xD;
&#xD;
               7. Subjects with other heart disease with significant clinical significance.&#xD;
&#xD;
          -  Sustained systolic blood pressure &gt;160 mm Hg and/or diastolic blood pressure &gt;100 mm&#xD;
             Hg after antihypertensive medication.&#xD;
&#xD;
          -  Fever and neutropenia occurred within 1 week before the first dose of 609A.&#xD;
&#xD;
          -  Subjects who have had major surgery within 21 days before the first dose of 609A&#xD;
             ((excluding diagnostic biopsies).&#xD;
&#xD;
          -  Live attenuated vaccines were administered within 28 days before the first dose of&#xD;
             609A.&#xD;
&#xD;
          -  Patients who had received treatment with any herbal or alternative therapies or&#xD;
             Chinese prepared medicine within 7 days before the first dose of 609A.&#xD;
&#xD;
          -  History of primary immunodeficiency, stem cell or organ transplant, or previous&#xD;
             clinical diagnosis of tuberculosis disease.&#xD;
&#xD;
          -  Subjects with active autoimmune diseases or history of autoimmune diseases should be&#xD;
             excluded; these include but are not limited to subjects with a history of immune&#xD;
             related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy,&#xD;
             Guillain- Barre syndrome, myasthenia gravis, systemic lupus erythematosus (SLE),&#xD;
             connective tissue diseases, scleroderma, inflammatory bowel disease including Crohn's&#xD;
             disease and ulcerative colitis, hepatitis, toxic epidermal necrolysis (TEN),&#xD;
             Stevens-Johnson syndrome, or antiphospholipid syndrome.&#xD;
&#xD;
          -  Subjects with condition requiring systemic treatment with either corticosteroids (&gt;15&#xD;
             mg/day prednisone or equivalent) or other immunosuppressive medications within 14 days&#xD;
             before the planned first dose of study drug. Inhaled or topical steroids, and adrenal&#xD;
             replacement steroid doses ≤ 10 mg daily prednisone equivalent are permitted in the&#xD;
             absence of active autoimmune disease. Ophthalmologic, nasal and intra-articular&#xD;
             injections of steroids are acceptable.&#xD;
&#xD;
          -  Any other serious underlying medical (e.g. uncontrolled diabetes mellitus, active&#xD;
             uncontrolled infection, active gastric ulcer, uncontrolled seizures, cerebrovascular&#xD;
             incidents, gastrointestinal bleeding, severe signs and symptoms of clotting&#xD;
             disorders), psychiatric, psychological, familial or geographical condition that, in&#xD;
             the judgment of the investigator, may interfere with the planned staging, treatment&#xD;
             and follow-up, affect subject compliance or place the subject at high risk from&#xD;
             treatment-related complications.&#xD;
&#xD;
          -  Any other conditions not suitable for subjects to be enrolled in this study, as&#xD;
             determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gang Tong</last_name>
    <phone>+86- 21- 021-50793963</phone>
    <email>tonggang@3sbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer hospital Chinese academy of medical sceience</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jie Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shuhang Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>September 5, 2020</last_update_submitted>
  <last_update_submitted_qc>September 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

